MannKind | MNKD - Sales Revenues


MannKind reported $111.96M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Adma Biologics USD 139.16M 4.94M Dec/2025
BioCryst Pharmaceuticals USD 406.56M 247.16M Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Halozyme Therapeutics USD 451.76M 97.76M Dec/2025
Insmed USD 263.8M 121.8M Dec/2025
Karyopharm Therapeutics USD 30.54M 8.24M Dec/2024
MacroGenics USD 41.23M 31.61M Dec/2025
MannKind USD 111.96M 29.83M Dec/2025
Merck USD 16.4B 880M Dec/2025
Minerva Neurosciences USD 0 0 Sep/2024
Novavax USD 147.14M 76.69M Dec/2025
Novo Nordisk DKK 12.53B 560M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
Sanofi EUR 11.3B 1.13B Dec/2025
Xencor USD 28.24M 7.24M Dec/2025